Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA
Published Time:
2024-09-24 17:26
Source:
At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.
Earlier this year in June, the Phase I clinical data of VC004 for tumors was impressively presented at ASCO 2024. The data showed superiority to first-generation drugs targeting in treating treatment-naive patients and exhibits significant curative effects in first-gen resistant patients. Moreover, the overall safety is good in all patients. Currently, VC004 is in the patient’s follow-up and pre-New Drug Application (NDA) preparation stage in China.
Clinically, VC004 is for treating patients with NTRK gene fusion-positive tumors and is not limited to specific cancer types. Compared with first-generation drugs targeting the same site, VC004 not only has stronger inhibitory activity against wild-type kinases but also features a unique anti-resistance mechanism, which is expected to extend the duration of clinical benefit for patients.
Currently, the first-generation drugs approved in the US are unable to solve the problem of secondary resistance in treatment-naive patients. Additionally, second-generation drugs demonstrate inferior efficacy in treatment-naive patients compared to first-generation drugs. Moreover, no second-generation drugs have been approved for marketing in China, leaving unmet clinical needs. In the future, the approval and launch of VC004 are expected to offer a potential optimal treatment option for treatment-naive and resistant patients in China, the US, and even globally.
Related News
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn